Jun 2026 (Q2 FY26) — Aug 6, 2026
Arcturus Therapeutics Q2 FY26 — Strategic Regaining of Vaccine Rights and Pipeline Progress
Read the full callArcturus Therapeutics (ARCT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Arcturus Therapeutics earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 3.0 | −89.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -863.3 | −822.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -23.8 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$11.27 +1.35% · +$0.15
Performance −47.0% 1Y
1Y: $21.25 on 14 Oct 2025 → $11.27. High $23.16 (21 Oct 2025), low $5.53 (24 Jul 2026).
- Previous close
- $11.12
- 52-week range
- $5.53 – $23.16
- One year
- −47.75%
Overview
- Symbol
- ARCT
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Arcturus Therapeutics earnings calls (ARCT)
Financials
What the filings say
Net profit, year on year: −159% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 42 | 23 | 29 | 28 | 17 | 7 | 2 | 3 |
| Operating profit | -11 | -33 | -17 | -12 | -17 | -31 | -29 | -26 |
| Operating margin | −25.8% | −146.7% | −57.3% | −41.0% | −96.3% | −435.0% | −1403.7% | −863.3% |
| Profit before tax | -7 | 132 | -14 | -9 | -13 | -29 | — | -24 |
| Tax rate | 3.0% | 0.0% | 0.0% | −0.0% | — | — | — | 0.0% |
| Net profit | -7 | -30 | -14 | -9 | -13 | -29 | -27 | -24 |
| EPS ($ per share) | -0.26 | — | -0.52 | -0.34 | -0.49 | — | -0.95 | -0.84 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -45 | -72 | -144 | -347 | -338 | -368 | -449 | -515 |
| Total liabilities | 31 | 56 | 80 | 165 | 180 | 151 | 103 | 57 |
| Fixed assets | 2 | 2 | 3 | 6 | 12 | 12 | 10 | 7 |
| Total assets | 44 | 82 | 476 | 393 | 450 | 429 | 344 | 271 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -21 | -6 | -43 | -135 | 32 | -18 | -60 | -74 |
| Cash from investing | 22 | -1 | -2 | -3 | -8 | -3 | -1 | -0 |
| Cash from financing | 10 | 42 | 436 | 48 | -3 | -24 | 5 | 13 |
| Net cash flow | 12 | 35 | 392 | -90 | 21 | -45 | -55 | -61 |
| Capital expenditure | -1 | -1 | -2 | -3 | -8 | -3 | -1 | -0 |
| Free cash flow | -22 | -7 | -45 | -138 | 24 | -21 | -60 | -75 |
Insider filings
No filings in the last 12 months.
No officer, director or 10% owner of ARCT filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Arcturus Therapeutics Holdings Inc.
Free account. Everything above stays public.
Write why you follow Arcturus Therapeutics Holdings Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading